Guardant Health (GH) director logs 232 RSUs converting to common stock

Rhea-AI Filing Summary

Guardant Health director Manuel Hidalgo Medina reported a routine equity award vesting. On January 17, 2026, 232 Restricted Stock Units converted at an exercise price of $0 into 232 shares of common stock. After this transaction, he beneficially owned 1,261 shares of common stock directly and 6,961 Restricted Stock Units.

The Restricted Stock Units were granted on July 17, 2024 and vest over four years. 25% of the award vested on the one-year anniversary of that grant date, and the remaining 75% vests in equal monthly installments over the following three years.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hidalgo Medina Manuel

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/17/2026		M		232	A	$0	1,261	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	01/17/2026		M			232	(1)	(2)	Common Stock	232	$0	6,961	D

Explanation of Responses:

1. The restricted stock unit award granted on July 17, 2024 vests over a four-year period. 25% of the shares subject to such award vested on the one-year anniversary of July 17, 2024 and the remaining 75% vests monthly for the three-year period thereafter.

2. Not applicable for Restricted Stock Units.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Manuel Hidalgo Medina	01/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Guardant Health (GH) report in this Form 4?

The filing reports that director Manuel Hidalgo Medina had 232 Restricted Stock Units convert into 232 shares of Guardant Health common stock on January 17, 2026 at an exercise price of $0.

How many Guardant Health shares does Manuel Hidalgo Medina own after this transaction?

Following the reported transaction, Manuel Hidalgo Medina beneficially owned 1,261 shares of Guardant Health common stock directly and 6,961 Restricted Stock Units.

What are the terms of Manuel Hidalgo Medina’s Guardant Health Restricted Stock Units?

The Restricted Stock Units were granted on July 17, 2024. 25% of the shares vested on the one-year anniversary of that date, and the remaining 75% vest monthly over the subsequent three-year period.

What transaction code is used in this Guardant Health (GH) Form 4?

The transaction is coded M, indicating an exercise or conversion of derivative securities (here, Restricted Stock Units) into Guardant Health common stock.

Is this Guardant Health Form 4 transaction a purchase or sale on the open market?

No open-market trade is reported. The Form 4 shows a conversion of Restricted Stock Units into common stock at an exercise price of $0, rather than a market purchase or sale.

What is Manuel Hidalgo Medina’s role at Guardant Health?

The Form 4 lists Manuel Hidalgo Medina’s relationship to Guardant Health as a director, with no officer or 10% owner status indicated.